Table 1.
Summary of Results for the Current Study
| Variable | Non-Prolonged | Prolonged | P Value |
|---|---|---|---|
| Number of eyes | 42 | 17 | |
| Male/female | 34/8 | 14/3 | 1 |
| Age (y) | 45.3 ± 8.2 | 47.1 ± 9.4 | 0.492 |
| Time from onset to initial visit (d) | 11.3 ± 9.3 | 14.5 ± 9.4 | 0.179 |
| Oral kallidinogenase use | 18 | 9 | 0.569 |
| Spherical equivalent (D) | –1.15 ± 1.68 | –1.01 ± 2.63 | 1 |
| BCVA (LogMAR) | –0.05 ± 0.15 | 0.01 ± 0.20 | 0.217 |
| BCVA (LogMAR) in 3 months | –0.08 ± 0.092 | –0.03 ± 0.14 | 0.208 |
| CRT (µm) | 390.3 ± 141.3 | 450.1 ± 169.0 | 0.245 |
| CCT (µm) | 365.8 ± 94.9 | 432.7 ± 123.2 | 0.0441 |
| SRFH (µm) | 261.9 ± 141.7 | 335.1 ± 172.4 | 0.128 |
| ONL (µm) | 84.8 ± 21.2 | 75.2 ± 19.0 | 0.183 |
| SRF duration (d) | 53.8 ± 25.2 | 201.9 ± 112.63 | – |
Significant difference between the two groups (P < 0.05).
Fifteen patients with early SRF resolution stopped visiting our hospital after less than 3 months, which is the average and mean deviation of the 27 patients.
SRF duration in prolonged group was recorded only in 8 cases without topical treatments, such as photocoagulation, PDT, or intravitreous injection of anti-VEGF, because the other 9 cases received such the treatment with SRF 3 months after the initial visit.
SRF, subretinal fluid; BCVA, best-corrected visual acuity; LogMAR: Converted to the logarithm of the minimal angle of resolution; CRT, central retinal thickness; CCT, central choroidal thickness; SRFH, subretinal fluid height; ONL, outer nuclear layer thickness; SRF duration, time from initial visit to SRF resolution.